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Summary
 
The product of the Philadelphia chromosome (Ph) translocation, the 
 
BCR/ABL
 
 oncogene, exists
in three principal forms (P190, P210, and P230 
 
BCR/ABL
 
) that are found in distinct forms of
Ph-positive leukemia, suggesting the three proteins have different leukemogenic activity. We
have directly compared the tyrosine kinase activity, in vitro transformation properties, and in vivo
leukemogenic activity of the P190, P210, and P230 forms of 
 
BCR/ABL
 
. P230 exhibited lower
intrinsic tyrosine kinase activity than P210 and P190. Although all three oncogenes transformed
both myeloid (32D cl3) and lymphoid (Ba/F3) interleukin (IL)-3–dependent cell lines to become
independent of IL-3 for survival and growth, their ability to stimulate proliferation of Ba/F3 lym-
phoid cells differed and correlated directly with tyrosine kinase activity. In a murine bone marrow
transduction/transplantation model, the three forms of 
 
BCR/ABL
 
 were equally potent in the in-
duction of a chronic myeloid leukemia (CML)–like myeloproliferative syndrome in recipient mice
when 5-fluorouracil (5-FU)–treated donors were used. Analysis of proviral integration showed the
CML-like disease to be polyclonal and to involve multiple myeloid and B lymphoid lineages, im-
plicating a primitive multipotential target cell. Secondary transplantation revealed that only cer-
tain minor clones gave rise to day 12 spleen colonies and induced disease in secondary recipients,
suggesting heterogeneity among the target cell population. In contrast, when marrow from non–
5-FU–treated donors was used, a mixture of CML-like disease, B lymphoid acute leukemia, and
macrophage tumors was observed in recipients. P190 
 
BCR/ABL
 
 induced lymphoid leukemia
with shorter latency than P210 or P230. The lymphoid leukemias and macrophage tumors had
provirus integration patterns that were oligo- or monoclonal and limited to the tumor cells, sug-
gesting a lineage-restricted target cell with a requirement for additional events in addition to
 
BCR/ABL
 
 transduction for full malignant transformation. These results do not support the hy-
pothesis that P230 
 
BCR/ABL
 
 induces a distinct and less aggressive form of CML in humans, and
suggest that the rarity of P190 
 
BCR/ABL
 
 in human CML may reflect infrequent 
 
BCR
 
 intron 1
breakpoints during the genesis of the Ph chromosome in stem cells, rather than intrinsic differ-
ences in myeloid leukemogenicity between P190 and P210.
Key words: Abelson virus • retroviral vector • chronic myelogenous leukemia • mouse cancer 
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T
 
he 
 
BCR/ABL
 
 fusion oncogene, the product of the
t(9;22) Philadelphia chromosome (Ph),
 
1
 
 exists in three
principal forms (P190, P210, and P230) that arise from dis-
tinct breakpoints in the 
 
BCR
 
 gene on chromosome 22, re-
sulting in translocation of 
 
BCR
 
 exon 1 (1), exons 1–12/13
(2), or exons 1–19 (3), respectively, to the c-
 
ABL
 
 gene on
chromosome 9. These different oncogenes give rise to
three distinct fusion proteins of molecular mass 190, 210,
and 230 kD, which contain the same portion of the c-Abl
tyrosine kinase in the COOH terminus but include differ-
ent amounts of Bcr sequence at the NH
 
2
 
 terminus.
 
1
 
Abbreviations used in this paper:
 
 ALL, acute B lymphoid leukemia; CML,
chronic myeloid leukemia; 5-FU, 5-fluorouracil; GST, glutathione 
 
S
 
-trans-
ferase; MSCV, murine stem cell virus; Ph, Philadelphia (chromosome);
STAT, signal transducer and activator of transcription. 
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Different Leukemogenic Activity of P190, P210, and P230 
 
BCR/ABL
 
In humans, there is evidence that the three different forms
of 
 
BCR/ABL
 
 are associated with distinct forms of leukemia
(for reviews, see references 4 and 5). The P210 form of
 
BCR/ABL
 
 is found in hematopoietic cells of patients with
chronic myeloid leukemia (CML) in stable phase, and in
acute lymphoid and myeloid leukemias (6–8), although
some patients with acute leukemia and P210 are likely to
be cases of CML diagnosed in blast crisis. In contrast, the
P190 form of 
 
BCR/ABL
 
 is commonly found in Ph-posi-
tive acute B lymphoid leukemia (ALL [9]) and occasionally
in acute myeloid leukemia (10), but is rarely if ever observed
in CML (11–13). Recently, several patients were described
who had a Ph-positive myeloproliferative syndrome resem-
bling CML but with very mild clinical symptoms, includ-
ing a lower peripheral blood white cell count consisting
principally of neutrophils, less anemia, less severe spleno-
megaly, and a delayed or absent transformation to blast cri-
sis (14). These patients were found to have the 
 
BCR
 
 exon
19/
 
ABL
 
 exon 2 (e19/a2) junction characteristic of P230
 
BCR/ABL
 
. It was proposed that patients with the e19/a2
fusion comprise a distinct clinical entity called neutrophilic
CML, with a much more benign clinical course than that
associated with the traditional b2/a2 or b3/a2 P210 
 
BCR/
ABL
 
 fusion. However, several subsequent reports described
patients with the e19/a2 fusion and typical CML (15–17).
These observations raise the question of whether different
forms of Bcr/Abl protein have intrinsically different leu-
kemogenic activity in hematopoietic cells.
Consideration of the primary structures of P190, P210, and
P230 indicates that P210 and P230 contain several potential
functional motifs encoded by the 
 
BCR
 
 portion of the fusion
gene (Cdc24/Dbl and plekstrin homology domains and a
portion of a RacGAP catalytic domain, respectively) that
might plausibly alter the oncogenic activity of these larger
proteins relative to P190. Indeed, characterization of the ty-
rosine kinase and in vitro transformation activities of P190
and P210 Bcr/Abl has suggested that these proteins have dis-
tinct transforming properties. In an immune complex kinase
assay, P190 has higher tyrosine kinase than P210, with P190
and P210 activity both elevated relative to c-Abl (18, 19).
P190 is more efficient than P210 in transformation of Rat-1
fibroblasts, as assessed by colony formation in soft agar (18).
Both P210 and P190 
 
BCR/ABL
 
 can stimulate the growth of
primary B cells in long-term in vitro cultures, eventually lead-
ing to oligoclonal populations of pre-B cells that are indepen-
dent of stroma and leukemogenic in syngeneic mice (20).
P190 is more potent than P210 in this growth-stimulatory as-
say, with P190-transduced cultures reaching high cell density
and stromal independence more frequently and sooner than
with P210 (21). The mechanism of increased growth stimula-
tion of B lymphoid cells by P190 is not known. Most studies
of P190 and P210 have found similar sets of tyrosine-phos-
phorylated proteins in cells transformed by the two on-
cogenes (22). A notable exception is signal transducer and
activator of transcription STAT6, a transcription factor nor-
mally activated by IL-4 and implicated in lymphoid prolifera-
tive responses (23) that is preferentially tyrosine phosphory-
lated and activated by P190 but not P210 Bcr/Abl (24).
The only model system where Bcr/Abl induces a myelo-
proliferative syndrome closely resembling human CML is
retroviral transduction of mouse bone marrow in vitro, fol-
lowed by transplantation of transduced cells into irradiated
syngeneic recipients (for a review, see reference 25). In this
assay, the P210 form of 
 
BCR/ABL
 
 induced a fatal CML-
like syndrome with massive elevation of neutrophils and
maturing myeloid cells in peripheral blood, marrow, spleen,
and liver (26–29). In addition to the CML-like syndrome,
other transplanted mice developed leukemias of B lymphoid,
monocyte/macrophage, T lymphoid, or erythroid lineages
(26, 30). Because these mice develop leukemias that closely
resemble several human Ph-positive leukemias, the bone
marrow transduction/transplant model is perhaps the best
system for directly comparing the leukemogenic activity of
different forms of 
 
BCR/ABL
 
. However, as originally de-
scribed, the system was hampered by difficulty in generat-
ing high-titer replication-defective 
 
BCR/ABL
 
 retrovirus
stocks, leading to a low efficiency of generation of diseased
animals. Under the best circumstances, the CML-like syn-
drome was observed in only 
 
z
 
25% of transplant recipients,
and some transplanted mice did not develop any malignan-
cies (26). Despite these difficulties, P190 was observed to
induce a similar CML-like syndrome in mice at low fre-
quency (31). In experiments which used replication-com-
petent Moloney murine leukemia helper virus to increase
transduction efficiency, P190 was also observed to induce
myeloid leukemias with excess neutrophils, suggestive of
CML (32). In addition, the latency of P190-induced my-
eloid and lymphoid leukemias after transplant was shorter
than for P210, suggesting that P190 was more potent in the
induction of both types of leukemia.
With modifications to the original bone marrow trans-
duction protocol, we and others (33) have recently been
able to obtain 100% incidence of the CML-like syndrome
in mice transplanted with P210 
 
BCR/ABL
 
-transduced mar-
row, allowing this method to be used as an assay for the
first time. Here, we report a direct comparison of the tyro-
sine kinase activity, in vitro transformation properties, and
in vivo leukemogenic activity of the P190, P210, and P230
forms of 
 
BCR/ABL
 
.
 
Materials and Methods
 
DNA Constructs.
 
A cDNA encoding the P230 form of 
 
BCR/
ABL
 
 was generated by a PCR strategy. A 5
 
9
 
 primer containing
the AatII site at nucleotide 3184 in the 
 
BCR
 
 cDNA open reading
frame and the adjacent e19/a2 
 
BCR/ABL
 
 junction sequence and
a 3
 
9
 
 primer containing the KpnI site at nucleotide 744 of the hu-
man c-
 
ABL
 
 type Ia cDNA were used to generate a 307-bp PCR
product from AatII to KpnI, spanning the P230 
 
BCR/ABL
 
 junc-
tion. The product was subcloned and completely sequenced to
verify the correct reading frame and lack of other mutations, then
used to generate a complete P230 cDNA. The P190, P210, and
P230 
 
BCR/ABL
 
 cDNAs were introduced as EcoRI fragments
into the unique EcoRI site of the murine stem cell virus (MSCV)-
based retroviral vector, MSCVneoEB (34).
 
In Vitro Kinase Assay.
 
Immunoprecipitation of Abl proteins
from transfected 293 cells or transduced Ba/F3 cells and immune 
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complex kinase assay was as described previously (19, 35), except
that a glutathione 
 
S
 
-transferase (GST)-c-Crk
 
120–225
 
 fusion protein
was used as an exogenous substrate. To normalize for the amount
of Abl proteins, cells were labeled for 12 h with [
 
35
 
S]
 
l
 
-methio-
nine before harvesting. The amount of 
 
32
 
P incorporation was
quantitated by PhosphorImager analysis (STORM 850; Molecu-
lar Dynamics), whereas 
 
35
 
S incorporation was quantitated by dig-
ital camera and analysis by NIH Image v1.59 software. Relative
protein levels, which were within 15% of one another, were cor-
rected for methionine content and used to normalize 
 
32
 
P incor-
poration to calculate relative kinase activity.
 
Generation of Retrovirus Stocks.
 
All DNAs were purified by
two rounds of buoyant density centrifugation in CsCl. 10 
 
m
 
g of
retroviral vector DNA and 5 
 
m
 
g of MCV-ecopac, an ecotropic
single-genome packaging construct (36), were transfected per 6-cm
dish of 293T cl. 17 cells (37), as described (36). Medium was
changed at 24 h, and virus supernatant was harvested at 48 h after
transfection. Supernatant was passed through a 0.45-
 
m
 
 filter, ali-
quoted, and frozen at 
 
2
 
80
 
8
 
C. An aliquot was thawed, the virus
titer for neomycin resistance was determined by transduction of
NIH 3T3 cells, and a screen for the presence of replication-com-
petent helper virus was carried out with a 
 
lacZ
 
-3T3 indicator cell
line. All viruses had titers of 3.5–4.0 
 
3
 
 10
 
6
 
 neomycin-resistant
CFU/ml, passed the correct proviral structure by Southern blot
analysis, and were free of detectable helper virus activity.
 
Transformation of Cytokine-dependent Hematopoietic Cell Lines.
 
32D cl3 cells and Ba/F3 cells were grown, transduced, and se-
lected for G418 resistance and IL-3 independence as described
previously (19). At 96 h after transduction, viable cells were
counted and plated at 4 
 
3
 
 10
 
4
 
 cells in 1.0 ml RPMI medium
without IL-3 and neomycin in triplicate wells of a 24-well plate.
Cells were incubated at 37
 
8
 
C, and the viable cell count was de-
termined daily for 3 d.
 
Bone Marrow Transduction and Transplantation.
 
All animal stud-
ies were approved by the Animal Use and Care Committees of
the Center for Blood Research and Harvard Medical School.
Balb/c mice (The Jackson Laboratory or Taconic Farms) from
6 to 12 wk of age were used in all experiments. In some experi-
ments, male donor mice were primed by intravenous injection
with 5-fluorouracil (5-FU; 200 mg/kg) 4 d before harvest. Male
donors were killed by CO
 
2
 
 asphyxiation, femur and tibia were
collected, and bone marrow was harvested by flushing with sy-
ringe and 26-gauge needle. Cells were counted and plated with-
out removal of erythrocytes at 2 
 
3
 
 10
 
7
 
 cells per 10-cm plate in
prestimulation medium (38) of DME, 15% (vol/vol) inactivated
FCS, 5% (vol/vol) WEHI-3B conditioned medium, penicillin/
streptomycin, 1.0 
 
m
 
g/ml ciprofloxacin, 200 
 
m
 
M 
 
l
 
-glutamine,
6 ng/ml recombinant murine IL-3 (Genzyme), 10 ng/ml recombi-
nant murine IL-6 (Genzyme), and 50–100 ng/ml recombinant mu-
rine stem cell factor (SCF; PeproTech). With non–5-FU–treated
marrow, 10 ng/ml recombinant murine IL-7 (Genzyme) was also
included. After prestimulation for 24 h at 37
 
8
 
C, viable cells were
counted and transduced with retroviral stocks in the same me-
dium containing 50% retroviral supernatant, 10 mM Hepes, pH
7.4, and 2 
 
m
 
g/ml polybrene. To increase transduction efficiency
(39), virus and cells were cosedimented at 1,000 
 
g
 
 for 90 min in a
Sorvall RT-6000 centrifuge. Medium was changed after a 2–4-h
adsorption period. At 48 h, a second round of transduction and
cosedimentation was performed, and the cells were collected 2 h
later, washed once in HBSS, and counted. Recipient female mice
were prepared by two doses of 450-cGy gamma irradiation sepa-
rated by 3 h. Transduced marrow cells were transplanted by in-
jection of 0.2–0.5 
 
3
 
 10
 
6
 
 cells (5-FU–treated marrow) or 1.0 
 
3
 
 10
 
6
 
cells (non–5-FU–treated marrow) in 0.4–0.5 ml HBSS into the
lateral tail vein. After transplant, recipients were housed in micro-
isolator cages supplied with acidified (pH 2.0) water.
 
Analysis of Diseased Mice.
 
After transplant, recipient mice were
evaluated daily for signs of morbidity, weight loss, failure to
thrive, and splenomegaly. Premorbid animals were killed by CO
 
2
 
asphyxiation, peripheral blood was obtained from the retroorbital
venous plexus, and hematopoietic tissues were removed. De-
pending on the individual animal, hematopoietic tissues and cells
were used for several applications, including histopathology, in
vitro culture, FACS
 
®
 
 analysis, secondary transplantation, genomic
DNA preparation, protein lysate preparation, or lineage analysis
(see below). The clinical features and histopathology of 
 
BCR/
ABL
 
-induced CML-like disease, B lymphoid leukemia, and mac-
rophage tumors were very similar to those observed previously (26).
 
Lineage Analysis.
 
Peripheral blood samples generally served as
a nearly pure source of neutrophils and their precursors; on occa-
sion, neutrophils were purified further by positive selection for
Ly-6G (Gr-1) antigen expression by immunomagnetic beads
(MicroMACS
 
®
 
; Miltenyi Biotec). Macrophages were isolated
from peritoneal washes, bone marrow, liver, or spleen by adher-
ence and often subsequent culture on bacterial petri dishes in the
presence of L929-conditioned medium as a source of CSF-1.
Erythroid cells were purified from spleen by sedimentation
through Ficoll-hypaque or by positive selection with TER119
mAb and immunomagnetic beads. B lymphoid cells were puri-
fied from pooled lymph nodes or spleen by positive selection
with anti-B220 mAb, and T cells were purified by isolation of
thymocytes or by positive selection of spleen or peripheral blood
with anti–Thy-1.2 mAb. In all cases, the purity of the population
was assessed by Wright-Giemsa staining of a cytospin specimen,
and only those samples with at least 80% purity as judged from
cell morphology were used for Southern blot analysis. Genomic
DNA was prepared from each population, digested with BglII,
and hybridized with a radioactive probe from the proviral neo-
mycin resistance gene to determine the number of distinct provi-
ral integrations in each sample. Subsequently, the blots were stripped
and reprobed with a radioactive probe from the human c-
 
ABL
 
gene that detects a common 2.2-kb fragment from all proviruses,
allowing determination of the total proviral content of each he-
matopoietic lineage. To control for differences in DNA loading,
the intensity of hybridization of a fragment from the endogenous
mouse c-
 
abl
 
 gene was used as an internal control. Intensity of hy-
bridization was determined by PhosphorImager analysis (Molecu-
lar Dynamics), and the ratio of intensity of hybridization of the
 
BCR/ABL
 
 fragment to murine c-
 
abl
 
 fragment was compared with
that of genomic DNA standards containing a single proviral copy,
with the results expressed as proviral copy number per diploid ge-
nome. A proviral copy number of 0.2 or less is consistent with the
absence of provirus from a particular hematopoietic lineage.
 
Secondary Transplants and Day 12 Spleen Colony Assay.
 
For adop-
tive transfer of the CML-like syndrome, 1–2 
 
3 
 
10
 
6
 
 bone marrow
and/or splenocytes from primary animals were injected intra-
venously into sublethally irradiated (450 cGy) female Balb/c recip-
ient mice. For isolation of day 12 spleen colonies, pairs of lethally
irradiated (900 cGy) Balb/c mice were injected intravenously with
3 
 
3
 
 10
 
3
 
, 1 
 
3
 
 10
 
4
 
, and 3 
 
3
 
 10
 
4
 
 nucleated marrow cells from pri-
mary animals. Recipients were killed 12 d later, spleens were iso-
lated, and macroscopic colonies were dissected out with the aid of
a stereoscopic microscope. For those colonies not visibly red in ap-
pearance, cytospin preparations were examined by Wright-Giemsa
staining to ensure the mixed myeloid origin of the colony. Geno-
mic DNA was then prepared and analyzed as described above. 
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BCR/ABL
Western Blot Analysis.
 
Protein lysates were prepared from pe-
ripheral blood myeloid cells by resuspension of 10
 
7
 
 cells in 75 
 
m
 
l
RIPA buffer with immediate addition of an equal volume of
95
 
8
 
C 2
 
3
 
 sample buffer and boiling for 10 min. Amounts of pro-
tein were standardized by SDS-PAGE and Coomassie blue stain-
ing. From other hematopoietic tissues and cultures, cell lysates in
RIPA were quantitated by Bio-Rad protein assay. SDS-PAGE
and Western blotting with anti-Abl (8E9; PharMingen) and an-
tiphosphotyrosine (4G10; Upstate Biotechnology, Inc.) antibod-
ies were performed as described (19).
 
Results
 
P230 Has Lower In Vitro Kinase Activity Than P210 and
P190.
 
Previous studies indicated that P190 Bcr/Abl had in-
trinsically higher tyrosine kinase activity, measured as auto-
phosphorylation or phosphorylation of an exogenous sub-
strate, than did P210, while both were higher than c-Abl (18,
19). In a direct comparison after immunoprecipitation from
transfected 293 cells, we again confirmed this and found a sig-
nificantly lower kinase activity for P230 Bcr/Abl (Fig. 1).
Corrected for levels of Abl protein, P190 had 7-fold in-
creased phosphorylation of a GST-Crk substrate relative to
c-Abl, whereas P210 and P230 had 5.4- and 3.7-fold in-
creased activity, respectively, with similar results for auto-
phosphorylation. There was no difference in the kinase
activity of c-Abl and the oncogenic SH3-deleted c-Abl
protein, as observed previously (40). Similar results were
obtained when the Bcr/Abl proteins were immunoprecipi-
tated from stably transformed Ba/F3 cells (see below; data
not shown).
The Three Forms of BCR/ABL Induce Different Proliferative
Responses in Cultured Lymphoid Cells. To compare the trans-
forming ability of the three BCR/ABL oncogenes in cul-
tured hematopoietic cells, we introduced them by retroviral
transduction into IL-3–dependent myeloid (32D cl3) and
lymphoid (Ba/F3) cell lines. P210 BCR/ABL has been pre-
viously demonstrated to transform each cell line to become
independent of IL-3 for survival and growth (41, 42) by a
mechanism that does not involve autocrine production of
growth factors. To avoid any differences due to prolonged
culture in the presence of BCR/ABL, populations of trans-
duced cells were selected in neomycin and immediately de-
prived of IL-3, with measurement of cell survival and prolif-
eration within 96 h of transduction. With both cell types,
populations of cells that were independent of IL-3 for sur-
vival and growth were selected with equal efficiency after
transduction with all three forms of BCR/ABL, but not with
the parental MSCVneoEB virus, demonstrating that P190,
P210, and P230 are all capable of transforming myeloid and
lymphoid cells to cytokine independence (Fig. 2). There was
no difference in the growth rate of 32D cells transduced
with any of the three forms of BCR/ABL in the absence of
IL-3 or of vector-transduced cells in the presence of IL-3
(Fig. 2 A). In contrast, BCR/ABL-transduced Ba/F3 cells
in the absence of IL-3 proliferated more slowly than vec-
tor-transduced cells in the presence of IL-3, with P190-
transduced cells showing the highest proliferation rate, fol-
lowed by P210 and then P230 (Fig. 2 B). The level of
expression of the three Bcr/Abl proteins and the spectrum
of tyrosine phosphorylated proteins were similar within each
of the two cell types (data not shown). These results suggest
that the three forms of BCR/ABL induce an identical pro-
liferative response in myeloid factor-dependent cells, but
deliver a submaximal growth stimulus in lymphoid cells
that parallels their intrinsic tyrosine kinase activity.
All Three Forms of BCR/ABL Induce an Identical CML-like
Syndrome in Mice. To compare directly the ability of the
three forms of BCR/ABL to induce a myeloproliferative
syndrome in mice, we used the bone marrow transduc-
tion/transplantation model system (26), with several modi-
fications to the original protocol designed principally to in-
crease transduction efficiency (see Materials and Methods).
With the modified protocol, we observed that all mice
transplanted with bone marrow transduced with each of
the three forms of BCR/ABL developed a fatal CML-like
myeloproliferative syndrome within 4 wk after transplanta-
tion when marrow from 5-FU–treated donors was used
(Fig. 3). The disease was characterized principally by mas-
sive expansion of maturing myeloid cells in bone marrow,
Figure 1. In vitro kinase activity of Bcr/Abl proteins. The indicated Abl
proteins were expressed by transient transfection of 293 cells, immunopre-
cipitated, and incubated with [g-32P]ATP and GST-Crk substrate as de-
scribed in Materials and Methods. (A) 35S incorporation into immunopre-
cipitated Abl proteins. (B) 32P label. The positions of c-Abl and Bcr/Abl
proteins and the GST-Crk substrate are indicated. (C) Coomassie blue stain
indicating equal amounts of GST-Crk substrate in each reaction. The trans-
kinase activity of each Abl protein, relative to c-Abl, is given at the top.1403 Li et al.
spleen, liver, and peripheral blood. The peripheral blood
leukocyte count at death was 2–4 3 105/ml, composed
predominantly of mature neutrophils, along with metamy-
elocytes, myelocytes, and promyelocytes, indicative of a
shift towards less differentiated myeloid cells. The spleen and
liver were greatly enlarged and disrupted by large numbers
of maturing myeloid cells from the neutrophil lineage,
along with significant erythropoiesis and increased mega-
karyocytes. Nearly all mice with the CML-like syndrome
also had small to medium-sized collections of macrophages
centered on portal areas in the liver. In addition, all animals
had focal consolidation of the lungs with maturing myeloid
cells and extensive intraparenchymal hemorrhage, which may
have been the ultimate cause of death of these animals.
Bone marrow showed increased cellularity with maturation
and an increased myeloid to erythroid ratio, while lymph
nodes and thymus were normal. In most cases, the CML-
like syndrome could be efficiently transferred to secondary
recipients by injection of bone marrow (data not shown),
but as previously reported (43), for some primary animals
the disease was not readily transplanted.
There was no significant difference in the histopathol-
ogy, average survival, peripheral blood leukocyte count, or
spleen weight of the disease induced by the three forms of
BCR/ABL (Fig. 3 insert, and data not shown). Because the
spleen is the main reservoir of myeloid cells in these dis-
eased mice, this implies that mice transplanted with P190-,
P210-, and P230-transduced marrow have identical total
myeloid cell burdens at death, indicating that the prolifera-
tive stimulus induced in myeloid cells by the three BCR/
Figure 2. Proliferation of fac-
tor-dependent hematopoietic cells
transformed by the three BCR/
ABL oncogenes. (A) 32D cl3 my-
eloid cells. (B) Ba/F3 lymphoid
cells. In each case, MSCVneo vec-
tor–transduced cells were grown
in either the presence or absence
of IL-3. The difference between
the day 2 mean cell number for
Ba/F3-MSCVneo (1IL-3) and
Ba/F3-P190, and between Ba/F3-
P190 and Ba/F3-P210 or Ba/F3-
P230 was significant (P 5 0.05, t
test). The difference between the
day 2 mean cell number between
Ba/F3-P210 and Ba/F3-P230 was
not significant.
Figure 3. The three forms of BCR/ABL
induce an identical CML-like disease in
mice. Survival curve for recipients of BCR/
ABL-transduced marrow from 5-FU–
treated donors. The individual mice in each
arm are indicated by the symbols. All ani-
mals developed the same CML-like syn-
drome (filled symbols). Similar survival
curves were observed in three independent
transplant experiments (data not shown).
(Insert) Similar myeloid cell levels in mice
with CML-like disease induced by the three
forms of BCR/ABL. Average 6 SE (bars)
of peripheral blood leukocyte count (3103/
ml, left) and spleen weight (in grams, right)
for the three different BCR/ABL geno-
types. The difference in mean survival of
P190-transduced versus P210-transduced
mice was significant at P 5 0.1 but not at
P 5 0.05 (t test); none of the other pairwise
differences in survival, leukocyte count, or
spleen weight were significant (P 5 0.1).
BMT, bone marrow transplantation.1404 Different Leukemogenic Activity of P190, P210, and P230 BCR/ABL
ABL oncogenes is very similar. Although human P1901
CMLs may be characterized by monocytosis (13), the per-
centage of monocytes in peripheral blood of mice with
CML-like disease was ,10% and did not differ significantly
between BCR/ABL genotypes (data not shown).
The CML-like Syndrome Is Polyclonal and Involves Several
Hematopoietic Lineages, Suggesting a Primitive Multipotential
Target Cell. Mice with the CML-like syndrome were ana-
lyzed for the presence of Bcr/Abl protein by Western blot
and for the BCR/ABL provirus by Southern blot of geno-
mic DNA. Bcr/Abl protein was detected in peripheral blood
leukocytes (principally neutrophils and their precursors; Fig.
4 A) and in peritoneal macrophages (Fig. 4 B), confirming
the expression of the BCR/ABL provirus in two distinct
myeloid lineages. To identify the BCR/ABL provirus,
genomic DNA from total spleen, liver, peripheral blood, or
bone marrow was digested with XbaI (which cuts once in
each proviral LTR) or BglII (which cuts once in proviral
DNA sequences 39 of the BCR/ABL cDNA insert) and
probed with a radioactive fragment from the neomycin resis-
tance gene. The XbaI digest indicated that these tissues con-
tained the BCR/ABL provirus at about one proviral copy
per cell (Fig. 5), confirming that the increased myeloid cells
in these animals were a primary part of the malignant process
and not a secondary or reactive phenomenon (30, 44). The
BglII digest, which yields a distinct hybridizing fragment for
each unique proviral integration site, demonstrated that mul-
tiple independent clones contributed to the myeloid cell ex-
pansion in these mice (Fig. 5), with 4–12 clones (average 9)
observed in recipients of P190-, P210-, and P230-trans-
duced marrow. Interestingly, the relative abundance of some
clones differed between DNA samples from the same animal,
suggesting a variable contribution of individual clones to
myelopoiesis in different tissues. The presence of polyclonal
disease suggests that the presence of BCR/ABL alone is suffi-
cient to induce the CML-like syndrome.
To determine which hematopoietic lineages were in-
volved in the malignant process, we performed lineage
analysis by purifying different hematopoietic cell popula-
tions and determining the BCR/ABL proviral status by
Southern blot. With all three oncogenes, mice with the
CML-like syndrome carried the BCR/ABL provirus at
or above single-copy levels in neutrophils, macrophages,
erythroid cells, and splenic B lymphoid cells, and in some
cases peripheral node lymphocytes and thymocytes (Fig. 6,
A–C). Most of the independent proviral clones present
were found in each lineage. These data indicate transduc-
tion of a bone marrow target cell capable of differentiation
via multiple myeloid and lymphoid pathways, suggesting
that the BCR/ABL target cell for the CML-like syndrome
is a multipotential progenitor cell.
To further define the nature of this target cell, we per-
formed secondary transplant experiments to isolate day 12
spleen colonies derived from selected primary mice with the
CML-like syndrome. Such colonies are clonal, of mixed my-
eloid origin, have limited self-renewal potential, and are de-
Figure 4. Detection of Bcr/Abl protein
in primary hematopoietic cells from mice
with BCR/ABL-induced leukemias. Ex-
tracts from cell lines expressing c-Abl or
P190, P210, or P230 Bcr/Abl are included
in each panel as size markers (lanes 1–3, 7–9,
and 18–20). Control extracts from spleno-
cytes or thioglycollate-induced peritoneal
macrophages from untransduced Balb/c
mice are included to demonstrate specificity
of anti-Abl staining (lanes 6, 13, and 17).
Top panels are anti-Abl blots; bottom pan-
els are the same membranes blotted with
antiphosphotyrosine (pTyr) antibody. (A)
Peripheral blood (predominantly neutro-
phils [PMN]) from two mice with P230-
(lane 4) and P210-induced (lane 5) CML-
like disease. (B) Primary macrophages (mf)
from mice with P210- (lanes 10 and 11) and
P230-induced (lane 12) CML-like disease,
and from mice with P210- (lanes 14 and 15)
and P230-induced (lane 16) primary mac-
rophage disease. (C) B lymphoid tumor cells
(B-ALL) from lymph node (LN, lane 21) or
pleural effusion (eff., lane 22) of two mice
with P230-induced disease, and from cul-
tured lymph node cells (LNCX, lane 23)
from a mouse with P190-induced disease.
Molecular weight markers are on the right.1405 Li et al.
rived from a cell (CFU-S12) with characteristics of an early
multipotential progenitor with some stem cell–like properties
(45). It was previously shown (26) that an animal with the
CML-like syndrome carried the retroviral provirus in the ma-
jority of secondary day 12 spleen colonies, suggesting that the
target cell for the CML-like syndrome was an early progeni-
tor that could generate CFU-S12. In this study, we also de-
tected the BCR/ABL provirus in the majority of day 12
spleen colonies in secondary transplants from mice with the
CML-like syndrome (Fig. 6, A, B, and D). Collectively, in
10 primary animals with the CML-like syndrome, 64% (28
out of 44) of day 12 spleen colonies from secondary trans-
plants carried the BCR/ABL provirus (Fig. 6, and data not
shown). Interestingly, of the many distinct proviral clones
present in the bone marrow of the primary animals, a small
subset of clones was detected frequently or exclusively in sec-
ondary day 12 spleen colonies. For example, two minor
clones were found in four out of seven colonies derived from
an animal with P190-induced CML-like disease (Fig. 6 A),
whereas a single minor clone generated seven out of eight
colonies from a mouse with P210-induced disease (Fig. 6 D).
We observed a similar phenomenon in secondary recipi-
ents that developed the CML-like syndrome after trans-
plantation of larger numbers of marrow cells. Instead of
developing polyclonal disease with the same spectrum of pro-
viral clones as the primary animal, myeloid cells from sec-
ondary mice with CML-like disease typically contained only
a single minor clone from the donor (Fig. 6, C and D). In
one animal, the same clone that contributed exclusively to
day 12 spleen colonies was also recovered from secondary
mice with CML-like disease (Fig. 6 D). These findings sug-
gest that the target cell for induction of the CML-like syn-
drome is heterogeneous, with all clones exhibiting multi-
lineage repopulating ability but only some clones capable of
efficient generation of CFU-S12 and secondary disease.
P190 BCR/ABL Induces More Aggressive B Lymphoid Leu-
kemia Than P210 or P230 When Non–5-FU–treated Marrow
Is Used for Transduction. Because animals with the CML-
like syndrome die within 4 wk of transplantation, it is not
possible to assess the incidence or severity of BCR/ABL-
induced hematologic malignancies of longer latency or
duration in this system. Multipotential myeloid target cells
for BCR/ABL are enriched for by 5-FU treatment (46),
whereas the target cell for Abelson virus–induced pre-B
leukemia is fairly abundant in normal marrow from Balb/c
mice (47). Therefore, we reasoned that the use of bone mar-
row from donors that had not been pretreated with 5-FU
might allow us to observe the characteristics of other leuke-
mias induced by BCR/ABL, including lymphoid leukemia.
Indeed, when marrow from non–5-FU–treated donors
was used for retroviral transduction, we observed three dis-
tinct hematopoietic neoplasms with each of the three forms
of BCR/ABL (Fig. 7). We observed the CML-like syn-
drome in about half of transplant recipients. The survival of
mice with the CML-like syndrome induced by transduc-
tion of non–5-FU marrow (21–49 d) was somewhat longer
than for recipients of 5-FU–treated marrow. Otherwise,
the syndrome appeared pathologically identical to that ob-
served with 5-FU–treated marrow, with increased neutro-
phil counts, hepatosplenomegaly, and pulmonary hemor-
rhage. Analysis of proviral integration in myeloid cells
showed that significantly fewer (one to three) independent
proviral clones contributed to the CML-like disease in
these mice, compared with recipients of transduced mar-
row from 5-FU–treated donors (Fig. 5). Lineage analysis of
selected mice demonstrated the same proviral clone(s) in
neutrophils, macrophages, erythroid cells, and B lymphoid
cells (data not shown), indicating the target cell for the
CML-like disease in normal marrow, like that from 5-FU–
treated marrow, had multilineage differentiation potential.
The other animals developed acute leukemia of B lym-
phoid type, or tumors of monocyte/macrophages. Animals
with B lymphoid leukemia exhibited modest splenomegaly
(0.2–0.4 g) and lymphadenopathy with infiltration with lym-
phoblasts, and a bloody pleural effusion, containing high lev-
els of malignant lymphoid cells, that appeared to be the cause
of death. The lymphoblasts expressed high levels of Bcr/Abl
protein (Fig. 4 C), were negative for myeloid and T lym-
phoid cell surface markers, but positive for CD45R (B220),
Figure 5. Polyclonal disease in mice with the CML-like syndrome.
Southern blot of genomic DNA from six mice with CML-like disease,
three receiving transduced marrow from 5-FU–treated donors (15-FU,
left) and three recipients of marrow from non–5-FU–treated donors (25-
FU, right). Genomic DNA from spleen, liver, peripheral blood (PB), or
bone marrow (BM) was digested with the indicated restriction enzyme,
transferred to nylon membranes, and hybridized with a radioactive probe
to the proviral neomycin resistance gene, as described in Materials and
Methods. In one case, Gr-11 peripheral blood neutrophils were isolated
from a P230-transduced animal with mixed CML and ALL. The XbaI di-
gest (X) yields a single full-length proviral species from each individual
clone, and indicates presence of the provirus at about single-copy levels in
myeloid cells of all four mice. The BglII digest (B) yields a distinct sized
species for each individual proviral integration. Control DNA samples
from a P210 BCR/ABL-transformed B cell line containing a single provi-
rus are used to indicate one proviral copy per diploid genome.1406 Different Leukemogenic Activity of P190, P210, and P230 BCR/ABL
CD43, 6C3/BP-1, and CD24 (data not shown), indicating
an immature B cell phenotype. The lymphoid leukemias
were efficiently transplanted to secondary recipients, with
animals receiving 3 3 106 tumor cells from lymph node or
pleural effusion succumbing to an identical disease within 4–5
wk. Animals with the monocyte/macrophage tumors pre-
sented with enlargement of the liver and infiltration of peri-
portal areas with tumors of cells with large vacuolated cyto-
plasm; similar tumors were often found in the spleen and
mesentery, and most animals had a prominent ascites com-
posed exclusively of macrophages. The tumor cells expressed
high levels of Bcr/Abl protein (Fig. 4 B) and were positive
for the cell surface markers Mac-1 and F4/80 but negative
for lymphoid markers (data not shown). Some mice exhib-
ited characteristics of two diseases simultaneously (Fig. 7);
because of the distinct and very uniform features of the three
Figure 6. The target cell for
the CML-like disease has multi-
lineage repopulating ability but is
heterogeneous for self-renewal as
assessed by secondary transplan-
tation. (A) Lineage analysis of a
primary animal with P190-
induced CML-like disease. In the
top panels, DNAs from the indi-
cated hematopoietic tissues and
lineages were digested with BglII
and hybridized with a radioac-
tive probe from the neomycin
resistance gene. The blot was
then stripped and reprobed with
a radioactive probe from the hu-
man c-ABL gene (bottom pan-
els), allowing determination of
the proviral copy number in
each sample (see Materials and
Methods). LN, pooled periph-
eral lymph nodes; p. blood, pe-
ripheral blood; BM, bone mar-
row; spleen T1191, T1192, and
B2201, splenocytes purified us-
ing mAbs against TER119 and
B220; per. mf, purified perito-
neal macrophages. Genomic
DNA from a control cell line
containing a single copy of the
BCR/ABL provirus is on the
left; DNAs from seven day 12
spleen colonies derived from
bone marrow from this animal
are on the right; one sample
contained two distinct proviral
integrants and likely represents a
mixture of two individual colo-
nies (CFU-S12 5/6). Provirus
was detected at 1.4–2.0 copies
per cell in several primary tissues,
indicating that one or more tar-
get cells had been transduced
with multiple proviruses. Puri-
fied TER1191 and B2201 sple-
nocytes contained the BCR/ABL
provirus at levels equal to or
higher than total spleen, indicat-
ing repopulation of erythroid
and B lymphoid lineages with
provirus-positive cells. (B) Lin-
eage analysis of a primary animal
with P230-induced CML-like disease. Nomenclature as in A. In this animal, provirus is absent from lymph node and thymus, but present in B2201 sple-
nocytes. Peritoneal macrophages from this animal were cultured for 1 wk in the presence of CSF-1 to increase cell number, resulting in selection for a
clone containing an amplified, rearranged provirus (data not shown); because of this frequent tendency, short-term adherence was used subsequently for
purification of macrophages. (C) Lineage analysis of a primary animal with P210-induced CML-like disease, and of a secondary marrow transplant recip-
ient from this mouse that also developed CML-like disease. Nomenclature as in A. At the right, spleen and bone marrow from the secondary (28) animal
carry two proviruses each present at single-copy levels, indicating a doubly transduced target cell. (D) Analysis of secondary transplants from an animal
with P210-induced CML-like disease. A single minor clone from the 13 clones present in the primary mouse (18) was selectively recovered from a sec-
ondary animal (28) with CML-like disease and from 7 out of 8 day 12 spleen colonies from this primary animal.1407 Li et al.
malignancies, it was relatively easy to recognize these animals
based upon clinical features and histopathology.
The survival curve of mice transplanted with P190-
transduced marrow differed significantly from that of P210-
or P230-transduced recipients (50% death in 25 d vs. 43
and 50 d, respectively; Fig. 7). Principally, this was because
P190 induced B lymphoid leukemia in the majority (6/8)
of recipients, which rapidly lead to the death of the host. In
contrast, recipients of P210- or P230-transduced marrow
that developed B lymphoid leukemia (3/9 and 5/7 mice,
respectively) succumbed to these diseases much later after
transplantation. The longer latency associated with P210 and
P230 appeared to reflect a longer time required for estab-
lishment of the disease rather than a more aggressive leuke-
mia, because the survival of secondary recipients trans-
planted with 3 3 106 malignant lymph node cells from
either P190- or P210-induced leukemia was similar, z4 wk
(data not shown). These data confirm earlier observations
on the relative potency of P190 and P210 BCR/ABL for in
vitro lymphoid transformation (21), and suggest that P190
induces lymphoid leukemia with shorter latency and per-
haps greater efficiency than either P210 or P230.
The Lymphoid Leukemias and Macrophage Tumors Are Oli-
go- or Monoclonal and Lineage Restricted. To further char-
acterize the lymphoid leukemias and macrophage tumors,
we analyzed genomic DNA from the primary tumors
(lymph node or pleural effusion cells for the lymphoid leu-
kemias, and liver, ascites, or purified macrophages for the
macrophage tumors). In addition, we performed lineage
analysis and isolated secondary day 12 spleen colonies from
selected mice. In contrast to the polyclonal nature of the
CML-like syndrome, we generally observed only one or
two independent proviral integrations in the lymphoid
leukemias and macrophage tumors (Fig. 8, A–C). In some
mice with lymphoid leukemia, different clones predomi-
nated in different anatomical sites such as lymph nodes and
the pleural effusion. The presence of oligo- or monoclonal
disease suggests that the presence of BCR/ABL alone is
insufficient to induce these diseases, and that secondary ge-
netic or epigenetic events are required.
In contrast to the CML-like syndrome, where provirus-
positive cells were observed in multiple myeloid and lym-
phoid lineages in addition to the neutrophils, the provirus
in the B lymphoid leukemias and macrophage tumors was
confined to the tumor cells, and not present in cells of
other hematopoietic lineages (Fig. 8, B and C). In animals
with the macrophage disease, provirus was absent from the
neutrophils, a closely related myeloid lineage. In those ani-
mals diagnosed with two diseases based on clinicopatholog-
ical criteria, two different proviral integrants were usually
observed, restricted to the individual tumors (26; Fig. 8 B,
and data not shown). In addition, provirus was uniformly
absent from day 12 spleen colonies derived from bone mar-
row of these mice; collectively, a total of 47 colonies derived
from 3 primary animals with lymphoid leukemia and 3 pri-
mary animals with macrophage disease lacked the retroviral
provirus (Fig. 8, B and C, and data not shown). These re-
sults suggest that the target cells for these diseases are pro-
genitor cells whose differentiation capacity is lineage re-
stricted and cannot give rise to CFU-S12.
Discussion
In human Ph-positive leukemia, the clear association of
different forms of the BCR/ABL oncogene with distinct
types of leukemia begs a biological explanation. This is
most evident for P190 BCR/ABL, which is only rarely if
ever observed in CML. Recently, it has been suggested
that the P230 form of BCR/ABL identifies a group of pa-
tients with a distinctly benign form of CML, neutrophilic
CML (14). There are two models that might explain such a
phenotypic correlation with different BCR/ABL geno-
types. It is possible that the three forms of BCR/ABL have
different intrinsic leukemogenic activities when expressed
in a hematopoietic progenitor cell that has acquired a t(9;
22) translocation. Alternatively, the three oncogenes might
have identical leukemogenic properties, but their expres-
sion might be largely restricted to different hematopoietic
lineages because a particular chromosome 22 breakpoint is
favored in a given lineage during the formation of the Ph
chromosome. For example, in this model, the BCR intron
1 breakpoint might be frequent in B lymphoid progenitor
Figure 7. Survival curve for recipients of
BCR/ABL-transduced marrow from non–
5-FU–treated donors. The individual mice
in each arm are indicated by the symbols.
Filled symbols, CML-like disease; open
symbols, B lymphoid leukemia; gray sym-
bols, macrophage disease. Animals diag-
nosed with two disease processes simulta-
neously based on histopathological and
molecular analysis are indicated by two-
color symbols. The difference in survival
between recipients of P190-transduced
marrow and either P210- or P230-trans-
duced marrow was highly significant (P ,
0.001, Cox test), whereas there was no sig-
nificant difference between P210 and P230.
BMT, bone marrow transplantation.1408 Different Leukemogenic Activity of P190, P210, and P230 BCR/ABL
cells but uncommon in hematopoietic stem cells, explain-
ing the rarity of P190 BCR/ABL in CML.
Several studies of the cell of origin of the Ph chromo-
some translocation appear to support the latter model. In
CML patients, the Ph chromosome is present in myeloid,
erythroid, megakaryocytic, and B lymphoid cells, confirm-
ing that the t(9;22) translocation took place in a very early
multipotential progenitor or stem cell (48). In Ph-positive
ALL, about half of adult patients have traditional BCR in-
tron 13 or 14 breakpoints on chromosome 22 generating
the P210 form of BCR/ABL. Some of these patients have
persistence of the Ph chromosome in remission and carry
the Ph chromosome in myeloid cells and myeloid colonies
grown in vitro, suggesting they represent cases of CML
presenting in blast crisis after an unrecognized chronic phase
(6–8, 49). In contrast, the majority of ALL patients with the
BCR intron 1 breakpoint characteristic of P190 BCR/ABL
do not exhibit the additional cytogenetic abnormalities
typical of CML blast crisis, lack the Ph chromosome in my-
eloid cells, and become Ph-negative during clinical remis-
sions, suggesting they represent transformation of a cell
type that is more limited in its differentiation potential (50).
However, some patients with P190-associated ALL show
persistence of the Ph chromosome in remission and in my-
eloid cells, suggesting a multipotential target cell (51–53).
Detailed studies of the nature of the cell of origin in patients
Figure 8. Oligoclonal and lineage-
restricted provirus integration patterns in
mice with BCR/ABL-induced B lymphoid
leukemia and macrophage disease. (A) Ge-
nomic DNA from lymph node or pleural
effusion of mice with BCR/ABL-induced
B lymphoid leukemia was digested with
EcoRI, transferred to nylon membranes,
and hybridized with a radioactive probe
from the neomycin resistance gene. Cyto-
spin analysis of lymph node and effusion
cells indicated .90% of all populations were
composed of malignant lymphoblasts. BLR1
denotes genomic DNA from primary bone
marrow or a marrow-derived cell line from
an animal with P190-induced B lymphoid
leukemia, while RN represents primary
lymph node and corresponding cell line
from an animal with P210-induced B lym-
phoid leukemia, both from earlier studies
(references 26 and 31), showing single provi-
ral integrations. (B) Lineage analysis of a
mouse with simultaneous BCR/ABL-
induced B lymphoid leukemia and macro-
phage disease. Nomenclature as in the leg-
end to Fig. 6. A single provirus is present in
B lymphoid blast cells isolated from spleen
(spleen B2201) and in three independent
cell lines derived from leukemic tissues,
whereas three distinct proviruses are found
at a total of one proviral copy per cell in
malignant peritoneal macrophages. Provirus
is absent from peripheral blood (z80% neu-
trophils), from bone marrow and spleen cells
that sedimented through Ficoll-Hypaque (ficoll pellet; entirely neutrophils and immature erythroid cells by cytospin analysis), and from splenic T lym-
phocytes (spleen Thy-11). Provirus was also absent from 14 day 12 spleen colonies derived from this mouse. (C) Lineage analysis of a mouse with BCR/ABL-
induced B lymphoid leukemia. This animal demonstrated two distinct proviral integrations in tumor cells, one predominant in lymph node and the other
in spleen and marrow, with both clones contributing to peripheral blood. Provirus is absent from peritoneal macrophages, bone marrow neutrophils, and
decreased in thymocytes and TER1191 splenocytes, both of which were contaminated with blasts at z25%.1409 Li et al.
with neutrophilic CML have not been reported. There-
fore, the available clinical and molecular studies of human
Ph-positive leukemia patients do not provide a biological
distinction between the above two models.
The purpose of this study was to characterize the kinase
activity and in vitro transformation properties of the newly
described P230 Bcr/Abl protein, and to compare the in vivo
leukemogenic activity of the three principal forms of Bcr/
Abl to distinguish between these alternative models. We
found elevated kinase activity for P230 Bcr/Abl relative to
c-Abl, although the activity of P230 was reproducibly lower
than that of P210. While all three forms of BCR/ABL trans-
formed IL-3–dependent myeloid and lymphoid cell lines to
IL-3 independence, they were all less effective than IL-3 at
promoting the growth of Ba/F3 lymphoid cells, with the
rates of proliferation directly correlating with the intrinsic ty-
rosine kinase activity of Bcr/Abl. The reason for this differ-
ence is not known, but it is plausible that increased tyrosine
phosphorylation of critical substrates such as STAT6 by P190
might contribute to proliferation.
To test the hypothesis that the three forms of BCR/ABL
have different leukemogenic properties in vivo, we used
the bone marrow transduction/transplantation model sys-
tem. This assay allowed us to directly determine whether
P190 is able to cause a CML-like syndrome and whether
P230 is less potent than P210 upon transduction of an
identical spectrum of primary hematopoietic cells. When
the three forms of BCR/ABL were transduced into mar-
row from donors treated with 5-FU, they induced an iden-
tical fatal CML-like disease in recipients transplanted with
the transduced cells, with no appreciable differences in histo-
pathology, hematologic parameters, or disease latency. These
observations argue that the three forms of BCR/ABL induce
an identical proliferative stimulus to myeloid cells in our ex-
perimental model. Human patients with neutrophilic CML
are described as having lower peripheral blood leukocyte
counts, less splenomegaly, and requiring little or no myelo-
suppressive therapy (14), features which imply less myeloid
cell proliferation and expansion relative to traditional CML.
However, our results do not support the hypothesis that
P230 generates a weaker proliferative stimulus in myeloid
cells than P210, and suggest that the mild clinical symptoms
observed in some patients with P230 BCR/ABL are due to
other variables, such as genetic differences between individu-
als or a selection bias (15–17). In recipients of transduced
marrow from non–5-FU–treated donors, there is a sugges-
tion of increased latency of P210- and P230-induced CML-
like disease compared with P190, which leaves open the
possibility of differences in BCR/ABL-induced CML-like
disease under conditions where small numbers of proviral
clones and perhaps lower Bcr/Abl expression exist.
Similarly, because P190 BCR/ABL can induce a CML-
like syndrome in mice which is identical to that induced by
P210, it is difficult to argue that the rarity of P190 in hu-
man CML reflects different leukemogenic activity of P190
in myeloid cells. Rather, our results suggest that the restric-
tion of P190 BCR/ABL to human acute leukemias may be
due to a relative lack of BCR first intron breakpoints dur-
ing the generation of the Ph chromosome in stem cells. Al-
ternatively, patients with the P190 form of BCR/ABL may
develop the Ph translocation in a stem cell but manifest
only a brief chronic phase. This is supported by a recent
study of human P190-positive ALL, where the Ph chromo-
some was detected by interphase fluorescence in situ hybrid-
ization in granulocytes of five out of five patients, suggest-
ing multilineage involvement (53).
Although there was no difference between the three
BCR/ABL oncogenes in induction of a CML-like disease
in recipients of transduced marrow from 5-FU–treated do-
nors, there was a highly significant difference in survival of
recipients of P190-transduced marrow compared with re-
cipients of P210- and P230-transduced marrow when do-
nors were not pretreated with 5-FU. Under these condi-
tions, rather than succumbing to CML-like disease, most
recipients of P190-transduced marrow developed B lym-
phoid leukemia. Although several recipients of P210- and
P230-transduced marrow also developed B lymphoid leu-
kemia, the disease developed significantly later with P210
and P230. These results demonstrate that P190 BCR/ABL
induces lymphoid leukemia in vivo with shorter latency
than P210 or P230, and are in agreement with previous
studies which found P190 to be more potent than P210 at
transformation of B lymphoid cells in vitro (21) and induc-
tion of lymphoid leukemia after marrow transduction (32).
Our data further suggest that P230 and P210 have similar
lymphoid leukemogenic activity. The mechanism of the
increased lymphoid leukemogenic activity of P190 relative
to P210 and P230 is not known. One possibility is that the
increased intrinsic tyrosine kinase activity of P190 allows
elevated tyrosine phosphorylation of a substrate critical to
proliferation or transformation of lymphoid cells. One can-
didate for such a key substrate is STAT6, whose DNA-
binding activity is activated via tyrosine phosphorylation by
P190 but not P210 (24). In support of this, we have ob-
served that bone marrow from stat62/2 mice (23) exhibits
significant resistance to transformation by P190 BCR/ABL
in vitro when compared with stat61/1 marrow (our un-
published observations). An alternative possibility is that
the presence of distinct functional motifs in the Bcr portion
of P210 and P230 BCR/ABL impairs lymphoid transfor-
mation by these oncogenes. The only known domain com-
mon to P210 and P230 but lacking in P190 is a homology
to Cdc24Hs/Dbl, which is a member of a class of guanine
nucleotide exchange factors for small G proteins of the
Rac/Cdc42 family. Our system allows us to readily test the
importance of this domain in lymphoid leukemogenesis.
What accounts for the very different spectrum of leuke-
mia observed when non–5-FU–treated marrow is used?
Data in this report argue that the CML-like disease, B lym-
phoid leukemia, and macrophage disease are the conse-
quence of BCR/ABL transduction of distinct bone marrow
target cells, and the relative abundance and/or infectability
of these target cells is influenced by 5-FU treatment of do-
nors. In mice with the CML-like syndrome, multiple my-
eloid and lymphoid lineages carry the same spectrum of
proviral clones, demonstrating that the target cell is a pro-1410 Different Leukemogenic Activity of P190, P210, and P230 BCR/ABL
genitor with both lymphoid and myeloerythroid differenti-
ation potential. In addition, we found the BCR/ABL
provirus in the majority of secondary day 12 spleen colo-
nies derived from primary mice with the CML-like syn-
drome, demonstrating that some of these target cells can
generate CFU-S12. In contrast, the bone marrow target
cells for induction of BCR/ABL-induced B lymphoid leu-
kemia and macrophage disease have restricted in vivo dif-
ferentiation potential, so that provirus-positive cells do not
contribute to other hematopoietic lineages; further, the
provirus is never found in day 12 spleen colonies derived
by secondary transplantation of marrow from these animals.
These observations suggest the BCR/ABL B lymphoid
leukemia target cell is a committed B lymphoid progenitor
similar or identical to the Abelson virus target cell, which is
known to be an immature Thy-1loB2201 committed lym-
phoid progenitor (54) that is distinct from CFU-S12 (55).
Analysis of proviral integration patterns suggests other
pathogenetic differences between BCR/ABL-induced CML-
like disease and B lymphoid leukemia. The CML-like dis-
ease observed in recipients of transduced marrow from
5-FU–treated donors is polyclonal, whereas the B lymphoid
leukemias are mono- or oligoclonal. The short latency of
the CML-like disease together with the polyclonal nature
suggest that BCR/ABL alone is capable of inducing CML-
like disease, whereas the longer latency and monoclonal
nature of the B lymphoid leukemias imply that expression
of  BCR/ABL alone may be insufficient for malignant
transformation of primary B lymphocytes and that addi-
tional events are required, a concept supported by many
previous observations (20, 56–59). However, proof of the
sufficiency of BCR/ABL for induction of the CML-like
disease will require limiting dilution analysis and knowl-
edge of the efficiency of infection of the CML target cell.
Interestingly, we and others (29) have found evidence
for heterogeneity among the presumptive target cells for
the murine CML-like syndrome. Of the many clones con-
tributing to the expansion of myeloid cells in several primary
CML animals, only one or two relatively minor clones were
observed to contribute to day 12 spleen colonies and to ef-
ficiently transfer the CML-like disease in secondary trans-
plants. These data imply two distinct target cells for the
murine CML-like syndrome, both with the capacity for
multilineage differentiation in the primary animal, but with
different ability for repopulation of secondary recipients.
These properties are reminiscent of the hierarchy of murine
hematopoietic stem cells, where a distinct population of
progenitor cells enriched for CFU-S12 has transient multi-
lineage repopulating and self-renewal potential, and a more
differentiated subset lacks secondary transplantability (60).
An alternative possibility is that all the CML target cells are
equivalent immediately after infection, but additional ge-
netic or epigenetic abnormalities confer transplantability on
a small subset of transduced progenitors. Distinguishing be-
tween these models will require isolation of the various tar-
get cells from whole marrow.
We found small to medium-sized accumulations of macro-
phages in the livers of nearly every animal with the CML-
like syndrome. Previous studies have shown that some ani-
mals with extensive BCR/ABL-induced macrophage tumors
exhibit elevated serum GM-CSF and/or G-CSF levels,
and a secondary elevation in peripheral blood neutrophils
that lack the retroviral provirus and are therefore not a di-
rect part of a malignant process (26, 30, 44). In our study,
immunoassay of plasma from several mice with primary or
secondary CML-like disease revealed normal levels of GM-
CSF but increased levels of IL-3 (data not shown). The bi-
ological significance of the elevation in plasma IL-3 in these
animals is not clear and is under investigation. However, in
contrast to mice with primary macrophage tumors, the neu-
trophils in all animals with the CML-like disease contain
the retroviral provirus and express Bcr/Abl protein, dem-
onstrating that this disease represents a bona fide myelopro-
liferative process. The lineage analysis suggests that the
macrophage collections in mice with the CML-like syn-
drome represent the product of differentiation of the my-
eloid clones, as previously suggested (32).
Our original goal in expressing BCR/ABL in the murine
hematopoietic system by retroviral transduction (26) was to
determine whether BCR/ABL was the direct cause of CML,
a point which has been established beyond reasonable doubt
(26–29). However, our initial model system was difficult to
use for comparative studies because of the low efficiency and
variability of induction of the CML-like disease. In this report,
the mouse bone marrow transduction/transplantation system
has been improved, and we have used this system for a direct
comparison of the leukemogenic properties of the three prin-
cipal forms of BCR/ABL. We found no significant difference
in the ability of the three oncogenes to induce a CML-like
myeloproliferative syndrome, but observed that P190 BCR/
ABL had increased potency for induction of B lymphoid leu-
kemia. This model system should be very useful for studying
the molecular pathophysiology of the Ph-positive leukemias,
such as testing the requirement for various functional domains
of Bcr/Abl, determining signaling pathways relevant to leuke-
mogenesis, and investigating the physiological effects of BCR/
ABL expression in primary hematopoietic cells.
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Note added in proof. Pear et al. (Pear, W.S., J.P. Miller, L. Xu, J.C. Pui, B. Soffer, R.C. Quackenbush, A.M.
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and Ren (Zhang, X., and R. Ren. 1998. Blood. 92:3829–3840) have also recently reported efficient induc-
tion of CML-like disease in mice by BCR/ABL.
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